Experts call for safer weight loss as concerns grow over GLP-1 use

Japanese cases of ketosis and ketoacidosis are prompting a closer look at how GLP-1 medications, restrictive dieting, and gaps in medical supervision can intersect during weight-loss attempts. https://www.news-medical.net/news/20260830/Experts-call-for-safer-weight-loss-as-concerns-grow-over-GLP-1-use.aspx A recent editorial published in the journal Diabetology International discussed the inappropriate use of glucagon-like peptide 1 (GLP-1)-based medications from clinical and regulatory perspectives.

A personalized elimination diet changed the gut microbiome in people with migraine

https://www.news-medical.net/news/20260831/A-personalized-elimination-diet-changed-the-gut-microbiome-in-people-with-migraine.aspx Researchers tracked gut bacteria, zonulin, and migraine-related biomarkers to test whether personalized food elimination could influence pathways connecting the gut and brain. In a recent randomized controlled trial published in the journal Frontiers in Nutrition, researchers investigated how food-specific immunoglobulin G (IgG)-guided elimination diets affected the gut microbiota and serum zonulin levels in adults with migraine. The study comprised a single-blind, sham-controlled trial involving 98 randomized migraine patients conducted over 12 weeks.

The scale told a similar story across three diets. The liver told a different one

When participants lost roughly the same amount of weight, changing the balance of carbohydrates, fats, and protein produced strikingly different metabolic responses, particularly in the liver. https://www.news-medical.net/news/20260831/The-scale-told-a-similar-story-across-three-diets-The-liver-told-a-different-one.aspx A recent randomized controlled trial (RCT) published in the journal Cell Metabolism suggests that dietary macronutrient composition may influence cardiometabolic responses to weight loss. Participants adhering to the very-low-carbohydrate ketogenic diet (KD) demonstrated greater reductions in liver fat compared with those following the Mediterranean and very-low-fat plant-forward diets.

Upping the Dose: Titration, Plateaus, and Patient Signals Jaime Almandoz, MD, MBA; Kevin R. Gendreau, MD; Noor A. Khan, MD; Christina N. Nguyen, MD;

https://www.medscape.com/viewarticle/upping-dose-titration-plateaus-and-patient-signals-2026a1000tfw?ecd=WNL_trdalrt_pos1_ous_260831_etid8647600&uac=148436CN&impID=8647600 Manufacturer labels call for GLP-1 dose increases every 4 weeks, but in practice, few physicians follow those recommendations. Medscape asked five obesity medicine specialists to share how they actually decide when to increase the GLP-1 dose, and the consensus was clear: The calendar matters less than the patient.

First blood test to personalize antidepressant treatment Developed by NeuroKaire, the blood-based test creates neurons from patient samples and analyzes their response to antidepressants to guide prescribing decisions. Written byBree Foster, PhD

First blood test to personalize antidepressant treatment Developed by NeuroKaire, the blood-based test creates neurons from patient samples and analyzes their response to antidepressants to guide prescribing decisions. Written byBree Foster, PhD https://www.drugdiscoverynews.com/first-blood-test-to-personalize-antidepressant-treatment-17124?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9xSlX5g3VZczmBmuHJicCxn7iIFO8UH96GeWQMShs3eGRKEy66c4D1LAl700X4NV_Fvlo-drZsIev9k1RAOQjAtgNExA&_hsmi=436086801&utm_content=436086801&utm_source=hs_email For patients seeking help for depression, starting treatment often marks the beginning of a long guessing game. More than half won’t respond to the first medication they try, and many will continue switching drugs without finding meaningful relief. That prolonged uncertainty has fueled growing calls for more personalized treatment strategies — ones that can shorten the path to effective care and reduce unnecessary suffering.

The next wave of psychedelics focuses on brain rewiring without the trip By separating therapeutic neuroplasticity from hallucinations, new psychedelic-inspired molecules could make treatment safer and more accessible. Written byBree Foster, PhD

The next wave of psychedelics focuses on brain rewiring without the trip By separating therapeutic neuroplasticity from hallucinations, new psychedelic-inspired molecules could make treatment safer and more accessible. Written byBree Foster, PhD https://www.drugdiscoverynews.com/the-next-wave-of-psychedelics-focuses-on-brain-rewiring-without-the-trip-17014?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9HP-ynVJEZyhGqtQb8Ui3rE7Pkyw-qDybouSCAvOeLqtGKWCpcPfVMscfYj9WmM2i_z-KX68x7b6R0zuoEq1bzv0P0ZQ&_hsmi=436086801&utm_content=436086801&utm_source=hs_email For decades, psychedelics like psilocybin and N,N-dimethyltryptamine (DMT) have intrigued scientists and clinicians with their ability to rapidly reshape the brain and improve mental health. Clinical trials have shown promise for conditions ranging from depression and anxiety to post-traumatic stress disorder (PTSD), but there is still a potential downside.

Moving beyond single targets in neurological repair Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability. Written byBree Foster, PhD

Moving beyond single targets in neurological repair Neuro-Innovators is testing whether a combination of existing medicines can promote neuroplasticity and improve outcomes for people living with chronic stroke disability. Written byBree Foster, PhD https://www.drugdiscoverynews.com/moving-beyond-single-targets-in-neurological-repair-17486?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8Wj_Hld4E05gX7n0IlfrlTQ9aUptJ5CEyt-k_Ee757PKgNJqrpy4EYJ9TMgOANZVoMOpb3Nps5mPhBfed3gIp0gGa2BA&_hsmi=436086801&utm_content=436086801&utm_source=hs_email Stroke is a leading cause of long-term disability worldwide, leaving many survivors with persistent impairments despite advances in acute treatment and rehabilitation. A key determinant of post-stroke recovery is the brain’s ability to reorganize its structure and function following injury, known as neuroplasticity. This process involves a complex network of interacting mechanisms, including changes in synaptic connections, neural circuitry, blood vessel formation, and inflammation. However, harnessing these separate mechanisms is extremely difficult.